{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:49:35Z","timestamp":1790617775006,"version":"4.1.0"},"reference-count":33,"publisher":"Society of Nuclear Medicine","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,3,25]]},"published-print":{"date-parts":[[2026,8]]},"DOI":"10.2967\/jnumed.126.272085","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:15:19Z","timestamp":1776870919000},"page":"1254-1260","source":"Crossref","is-referenced-by-count":2,"title":["Thrombotic Microangiopathy in Patients Treated with\n                    <sup>177<\/sup>\n                    Lu-PSMA Combination Therapies"],"prefix":"10.2967","volume":"67","author":[{"given":"Joanna C.","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell T.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Hitchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise K.","family":"Kostos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratheepan","family":"Puvanakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevastjian","family":"Kranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Tiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Buteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Price","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun A.","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Ruderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahneen","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"2026082505101113000_67.8.1254.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026082505101113000_67.8.1254.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00529-6"},{"key":"2026082505101113000_67.8.1254.3","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.annonc.2025.07.003","article-title":"Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer","volume":"36","author":"Fizazi","year":"2025","journal-title":"Ann Oncol."},{"key":"2026082505101113000_67.8.1254.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"2026082505101113000_67.8.1254.5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262713"},{"key":"2026082505101113000_67.8.1254.6","doi-asserted-by":"crossref","unstructured":"Tagawa ST . Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition). Presented at ESMO Congress 2025; October 2025; Berlin, Germany.","DOI":"10.1016\/j.annonc.2025.09.101"},{"key":"2026082505101113000_67.8.1254.7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.eururo.2022.05.025","article-title":"Extensive 177Lu-PSMA radioligand therapy can lead to radiation nephropathy with a renal thrombotic microangiopathy-like picture","volume":"83","author":"Sch\u00e4fer","year":"2023","journal-title":"Eur Urol."},{"key":"2026082505101113000_67.8.1254.8","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ekir.2024.11.009","article-title":"Thrombotic microangiopathy from peptide receptor radionuclide therapy","volume":"10","author":"Delalande","year":"2025","journal-title":"Kidney Int Rep."},{"key":"2026082505101113000_67.8.1254.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra020528"},{"key":"2026082505101113000_67.8.1254.10","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/ndt\/gfac213","article-title":"Retrospective study of 59 cases of cancer-associated thrombotic microangiopathy: presentation and treatment characteristics","volume":"38","author":"Decaestecker","year":"2023","journal-title":"Nephrol Dial Transplant."},{"key":"2026082505101113000_67.8.1254.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1312353"},{"key":"2026082505101113000_67.8.1254.12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.thromres.2023.02.012","article-title":"Eculizumab in the management of drug-induced thrombotic microangiopathy: a scoping review of the literature","volume":"224","author":"Zafar","year":"2023","journal-title":"Thromb Res."},{"key":"2026082505101113000_67.8.1254.13","doi-asserted-by":"crossref","first-page":"1088031","DOI":"10.3389\/fphar.2022.1088031","article-title":"Drug-induced thrombotic microangiopathy: an updated review of causative drugs, pathophysiology, and management","volume":"13","author":"Mazzierli","year":"2022","journal-title":"Front Pharmacol."},{"key":"2026082505101113000_67.8.1254.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00440-6"},{"key":"2026082505101113000_67.8.1254.15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.eururo.2023.08.026","article-title":"Administering [177Lu]Lu-PSMA-617 prior to radical prostatectomy in men with high-risk localised prostate cancer (LuTectomy): a single-centre, single-arm, phase 1\/2 study","volume":"85","author":"Eapen","year":"2024","journal-title":"Eur Urol."},{"key":"2026082505101113000_67.8.1254.16","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026082505101113000_67.8.1254.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.269252"},{"key":"2026082505101113000_67.8.1254.18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.269640"},{"key":"2026082505101113000_67.8.1254.19","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/S1470-2045(25)00559-5","article-title":"Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1\/2 trial","volume":"26","author":"Kostos","year":"2025","journal-title":"Lancet Oncol."},{"key":"2026082505101113000_67.8.1254.20","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1200\/JCO.2023.41.16_suppl.5005","article-title":"LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC) [abstract]","volume":"41","author":"Sandhu","year":"2023","journal-title":"J Clin Oncol."},{"key":"2026082505101113000_67.8.1254.21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2026082505101113000_67.8.1254.22","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.7150\/jca.63509","article-title":"Expression of prostate-specific membrane antigen (PSMA) in papillary renal cell carcinoma - overview and report on a large multicenter cohort","volume":"13","author":"Zsch\u00e4bitz","year":"2022","journal-title":"J Cancer."},{"key":"2026082505101113000_67.8.1254.23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268640"},{"key":"2026082505101113000_67.8.1254.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"2026082505101113000_67.8.1254.25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265986"},{"key":"2026082505101113000_67.8.1254.26","doi-asserted-by":"crossref","first-page":"101081","DOI":"10.1016\/j.tranon.2021.101081","article-title":"Thrombotic microangiopathy in oncology\u2014a review","volume":"14","author":"Valerio","year":"2021","journal-title":"Transl Oncol."},{"key":"2026082505101113000_67.8.1254.27","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/j.semnuclmed.2021.11.003","article-title":"Radiation dosimetry in 177Lu-PSMA-617 therapy","volume":"52","author":"Jackson","year":"2022","journal-title":"Semin Nucl Med."},{"key":"2026082505101113000_67.8.1254.28","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-005-0544-5"},{"key":"2026082505101113000_67.8.1254.29","doi-asserted-by":"publisher","DOI":"10.1016\/1078-1439(95)00002-Y"},{"key":"2026082505101113000_67.8.1254.30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s42399-023-01390-7","article-title":"A case of recurrent ovarian cancer with renal dysfunction associated with the use of olaparib","volume":"5","author":"Yamano","year":"2023","journal-title":"SN Compr Clin Med."},{"key":"2026082505101113000_67.8.1254.31","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1182\/bloodadvances.2024015777","article-title":"Advancements in complement inhibition for PNH and primary complement-mediated thrombotic microangiopathy","volume":"9","author":"Padilla Kelley","year":"2025","journal-title":"Blood Adv."},{"key":"2026082505101113000_67.8.1254.32","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1182\/blood.2021012860","article-title":"Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond","volume":"139","author":"Gavriilaki","year":"2022","journal-title":"Blood."},{"key":"2026082505101113000_67.8.1254.33","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood.2023022526","article-title":"A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation-associated TMA","volume":"143","author":"Jodele","year":"2024","journal-title":"Blood."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.126.272085","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:10:22Z","timestamp":1787659822000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.126.272085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,3]]},"published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.2967\/jnumed.126.272085"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.126.272085","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]}}}